GlobeNewswire: BioPorto A/S Contains the last 10 of 711 releaseshttp://www.globenewswire.com/External?Length=42024-03-30T08:30:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/22/2833304/0/en/BioPorto-announces-preliminary-results-for-2023-and-provides-strategic-update-for-the-period-2024-2026.html?f=22&fvtc=4&fvtv=8772BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-20262024-02-22T06:31:41Z<![CDATA[February 22, 2024]]>https://www.globenewswire.com/news-release/2024/02/20/2831519/0/en/Roche-Diagnostics-and-BioPorto-expand-collaboration.html?f=22&fvtc=4&fvtv=8772Roche Diagnostics and BioPorto expand collaboration2024-02-20T07:28:53Z<![CDATA[20 February 20, 2024Announcement no. 02]]>https://www.globenewswire.com/news-release/2024/02/19/2831058/0/en/BioPorto-A-S-to-host-investor-meetings-on-22-February-2024.html?f=22&fvtc=4&fvtv=8772BioPorto A/S to host investor meetings on 22 February 20242024-02-19T06:41:02Z<![CDATA[19 February 2024News Release]]>https://www.globenewswire.com/news-release/2024/01/09/2806619/0/en/BioPorto-implements-changes-to-the-Executive-Management.html?f=22&fvtc=4&fvtv=8772BioPorto implements changes to the Executive Management.2024-01-09T18:42:40Z<![CDATA[January 9, 2024]]>https://www.globenewswire.com/news-release/2023/12/09/2793441/0/en/Managers-transactions.html?f=22&fvtc=4&fvtv=8772Managers’ transactions2023-12-09T17:12:45Z<![CDATA[December 9, 2023]]>https://www.globenewswire.com/news-release/2023/12/08/2793291/0/en/FDA-Clears-First-Test-to-Identify-Hospitalized-Children-at-Risk-for-Acute-Kidney-Injury-AKI.html?f=22&fvtc=4&fvtv=8772FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI) 2023-12-08T16:02:14Z<![CDATA[8 December 2023]]>https://www.globenewswire.com/news-release/2023/12/08/2793000/0/en/BioPorto-modtager-FDA-godkendelse-i-USA-vedr%C3%B8rende-NGAL-Test-til-identificering-af-risiko-for-akut-nyresvigt-hos-b%C3%B8rn-i-alderen-3-m%C3%A5neder-til-21-%C3%A5r.html?f=22&fvtc=4&fvtv=8772BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år2023-12-08T07:13:11Z<![CDATA[8. december 2023]]>https://www.globenewswire.com/news-release/2023/12/07/2792907/0/en/BioPorto-Receives-FDA-510-k-Clearance-for-NGAL-Test-in-the-United-States-First-Test-to-Aid-in-Assessing-AKI-Risk-for-Patients-Aged-3-Months-Through-21-Years.html?f=22&fvtc=4&fvtv=8772BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years2023-12-07T21:22:45Z<![CDATA[December 7, 2023]]>https://www.globenewswire.com/news-release/2023/12/04/2790362/0/en/Resignation-of-Director.html?f=22&fvtc=4&fvtv=8772Resignation of Director2023-12-04T19:00:38Z<![CDATA[December 4, 2023Announcement no. 19]]>https://www.globenewswire.com/news-release/2023/11/01/2771587/0/en/BioPorto-Announces-Two-Poster-Presentations-at-ASN-Kidney-Week-2023-Conference.html?f=22&fvtc=4&fvtv=8772BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference2023-11-01T16:40:09Z<![CDATA[]]>